Neosynephrin-Pos (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Neosynephrin-Pos, is an alpha‑1 adrenergic agonist presented as an ophthalmic solution for ocular (topical) use. It produces rapid pupil dilation (mydriasis) for diagnostic eye examinations and constricts conjunctival blood vessels to lessen ocular redness.

GNH USA supplies Neosynephrin-Pos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across EU and global markets through validated manufacturing and distribution processes, and reliable cold‑chain logistics where required.

Phenylephrine Hydrochloride in Neosynephrin-Pos acts on alpha‑1 adrenergic receptors of the iris and conjunctival vessels, making it useful in several ophthalmic applications.

- Diagnostic eye examination: provides mydriasis to facilitate retinal assessment. - Pre‑operative preparation: dilates the pupil for intra‑ocular surgeries. - Ocular redness reduction: constricts conjunctival vessels to lessen visible redness.

Phenylephrine Hydrochloride may cause local and systemic reactions when applied to the eye.

Common Side Effects: - Stinging or burning sensation upon instillation. - Transient blurred vision. - Mild conjunctival hyperemia. - Temporary increase in intra‑ocular pressure. - Headache. - Mild allergic conjunctivitis.

Serious or Rare Side Effects: - Sustained elevation of intra‑ocular pressure, especially in glaucoma patients. - Systemic hypertension or tachycardia. - Severe allergic reaction (angio‑edema, anaphylaxis). - Corneal ulceration with prolonged use. - Retinal artery occlusion (very rare).

Before using Neosynephrin-Pos, consider the following safety measures.

- Assess intra‑ocular pressure: avoid in patients with narrow‑angle glaucoma. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Concomitant MAO inhibitors: avoid due to risk of hypertensive crisis. - Children: monitor for systemic absorption and limit exposure. - Contact lenses: remove lenses before administration and wait before reinserting. - Store at room temperature: keep in the original container, protect from light and moisture.

Phenylephrine may interact with other medications, altering its safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Tricyclic antidepressants: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: may affect pupil response. - Systemic sympathomimetics: increased cardiovascular stimulation. - Other topical vasoconstrictors: cumulative irritation risk.